News

Biofuels producers join forces
Enlarge image

PolicyBelgiumEUGermanyItalyUKFinland

Biofuels producers join forces

11.02.2013 - Seven leading producers of second generation biofuels have joined forces in an industry initiative to support uptake of their technology.

The initiative, named “Leaders of Sustainable Biofuels”, aims at supporting the development of second generation biofuels as a sustainable alternative to fossil fuels in Europe. The leaders of Chemtex, British Airways, BTG, Chemrec, Clariant, Dong Energy and UPM are joining forces to ensure the market uptake of advanced sustainable biofuels by all transport sectors. The Chief Executive Officers of the companies suggested biofuels were cost-competitive and had less environmental impact than fuels made from oil or natural gas. They argue that second-generation biofuels can reduce GHG emissions by at least 65%.

In contrast, first generation biofuels, made from corn, wheat, soy or palm provide only modest reductions in greenhouse gases and can push up food prices. At the initiative’s launch in Brussels, the “Leaders of Sustainable Biofuels” demanded to accelerate research and innovation into emerging biofuel technologies, including algae and new conversion pathways, supported by public and private R&D programmes. They said it were important to develop worldwide accepted sustainability certification and to establish financing structures to facilitate the implementation of sustainable biofuel projects. The initiative aims at promoting the benefits of advanced sustainable biofuels and to address national policy makers, the European Commission and the European Parliament. The “Leaders are convinced that their biofuels are key for the reduction of fossil energy imports in the EU”. 

© eurobiotechnews.eu/tg 

http://www.european-biotechnology-news.com/news/news/2013-01/biofuels-producers-join-forces.html

M&AIreland

31.03.2015 In its aim to expand its drug portfolio in orphan disease products, Horizon Pharma has acquired US company Hyperion Therapeutics for US$1.1bn in cash. The takeover entitles the UK biopharma to all of Hyperion’s common stock.

BusinessGermany

31.03.2015 Merck Serono has forged a US$941m (€876m) deal with US Intrexon for the development and commercialisation of CAR-T therapies. The new CAR-T projects are set to strengthen their R&D technology portfolio in immuno-oncology.

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

FinancingPoland

24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.

BioeconomyFranceSwedenGermanyNetherlandsFinland

23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.

Stock MarketsFranceSwedenUKNorwayIreland

20.03.2015 There are no signs of inertia creeping into the European biotech industry this spring. A total of eight IPOs are set to go public by the end of the year’s first quarter.

FinancingUKEU

17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.

FinancingFranceDenmarkSwedenGermany

19.03.2015 French venture capital firm Seventure Partners has raised a further €25m for its microbiome-focused Health for Life Capital Fund. It now stands at €100m.

EventsFranceEUSwitzerlandUKGermany

12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.

M&ABelgium

11.03.2015 Belgian cell-based therapeutics developer and CMO MaSTherCell SA has been acquired by US biotech Orgenesis Inc. for €23m.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC1.28 EUR10.34%
  • BASILEA110.70 CHF2.31%
  • BIOTEST98.10 EUR2.29%

FLOP

  • PAION2.36 EUR-6.72%
  • MOLOGEN5.45 EUR-4.22%
  • WILEX3.01 EUR-2.90%

TOP

  • CYTOS1.43 CHF320.6%
  • MEDIGENE12.31 EUR189.6%
  • 4SC1.28 EUR64.1%

FLOP

  • MORPHOSYS58.81 EUR-21.3%
  • WILEX3.01 EUR-12.2%
  • BASILEA110.70 CHF-9.4%

TOP

  • SANTHERA93.75 CHF2214.8%
  • FORMYCON26.94 EUR271.6%
  • WILEX3.01 EUR220.2%

FLOP

  • CYTOS1.43 CHF-52.3%
  • MOLOGEN5.45 EUR-52.0%
  • PAION2.36 EUR-35.0%

No liability assumed, Date: 31.03.2015